GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Cyclically Adjusted PB Ratio

CASI (CASI Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.39 (As of May. 25, 2025)


View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-25), CASI Pharmaceuticals's current share price is $1.87. CASI Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $4.75. CASI Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.39.

The historical rank and industry rank for CASI Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

CASI' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.28   Med: 1.25   Max: 10.56
Current: 0.39

During the past years, CASI Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 10.56. The lowest was 0.28. And the median was 1.25.

CASI's Cyclically Adjusted PB Ratio is ranked better than
75.45% of 668 companies
in the Biotechnology industry
Industry Median: 1.485 vs CASI: 0.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CASI Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was $-0.521. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.75 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


CASI Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Cyclically Adjusted PB Ratio Chart

CASI Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.67 1.53 0.33 1.44 0.60

CASI Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 1.17 1.29 0.60 0.45

Competitive Comparison of CASI Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

CASI Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CASI Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.87/4.75
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, CASI Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.521/115.1156*115.1156
=-0.521

Current CPI (Mar. 2025) = 115.1156.

CASI Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 -1.063 99.500 -1.230
201509 -1.459 100.500 -1.671
201512 -1.876 100.600 -2.147
201603 1.089 102.200 1.227
201606 2.111 101.400 2.397
201609 3.240 102.400 3.642
201612 3.452 102.600 3.873
201703 3.196 103.200 3.565
201706 2.828 103.100 3.158
201709 2.588 104.100 2.862
201712 5.520 104.500 6.081
201803 8.491 105.300 9.282
201806 9.655 104.900 10.595
201809 12.133 106.600 13.102
201812 11.487 106.500 12.416
201903 10.885 107.700 11.634
201906 9.302 107.700 9.942
201909 8.342 109.800 8.746
201912 7.466 111.200 7.729
202003 6.973 112.300 7.148
202006 6.276 110.400 6.544
202009 7.385 111.700 7.611
202012 6.579 111.500 6.792
202103 7.155 112.662 7.311
202106 6.781 111.769 6.984
202109 6.195 112.215 6.355
202112 6.044 113.108 6.151
202203 5.511 114.335 5.549
202206 4.920 114.558 4.944
202209 4.536 115.339 4.527
202212 3.312 115.116 3.312
202303 2.971 115.116 2.971
202306 2.419 114.558 2.431
202309 2.152 115.339 2.148
202312 1.806 114.781 1.811
202403 1.154 115.227 1.153
202406 0.625 114.781 0.627
202409 0.896 115.785 0.891
202412 0.119 114.893 0.119
202503 -0.521 115.116 -0.521

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CASI Pharmaceuticals  (NAS:CASI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CASI Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CASI Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 81, Jianguo Road, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Executives
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He director, 10 percent owner, officer: Chairman and CEO ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang officer: President 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd 10 percent owner LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski officer: Chief Medical Officer 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li 10 percent owner BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p. 10 percent owner UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc 10 percent owner 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd 10 percent owner P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren director, officer: CEO and Director 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065